Wu Xiaobin

BeOne President Wu Xiaobin sells entire 3,991-share position for $1.5M (100% stake liquidation)

Wu Xiaobin, President and COO of BeOne Medicines, executed 3 separate sales on 2025-11-17 totaling 3,991 shares for $1,518,302.85, eliminating his entire shareholding (from 3,991 shares to 0). The sales occurred at blended average price $380.43, just 7.5% above the current price of $353.79 and near the 52-week high of $377.47. This represents a complete exit by a senior executive. Notably, Wu has engaged in 5 prior sales at ONC within days (2025-11-12 through 2025-11-13), suggesting a sustained and accelerating liquidation pattern at this ticker. His cross-ticker track record shows 20 prior sells with average 90-day return of +22.0% and 0% well-timed rate—meaning those prior sells were poorly timed as the stock subsequently rose—though at ONC specifically, outcomes on those 5 recent trades remain unmeasured. The company carries extreme valuation metrics (P/E of 7075.80) and despite $1.4B quarterly revenue and +55% annual growth, reported negative full-year net income, creating fundamental tension with the current share price.

President/COO Wu Xiaobin sells entire 16.0K share stake for $5.8M at blended $365.22 (11/12–11/13)

Wu Xiaobin, President and COO of BeOne Medicines, executed 10 separate sales totaling 16,009 shares for $5,846,820.22 across two trading days (November 12–13, 2025), eliminating his entire open position. The liquidation occurred near the 52-week high ($377.47), with transaction prices ranging from $350.44 to $381.05. At the same-ticker level, Wu's five prior sales at ONC (all on 2025-08-14) saw subsequent 90-day gains ranging from +22.5% to +24.4%, yet none were well-timed in the directional sense (all showed stock appreciation after the sales, indicating poor exit timing on those earlier trades). The company reports a P/E of 7316.40 and was unprofitable over its most recent full fiscal year, despite recent strong revenue growth of +55.0% and latest-quarter revenue of $1.4B. The current stock price of $365.82 is -3.1% from the 52-week high and up +15.7% over the past 30 days, consistent with the elevated valuations at which these sales occurred.

President and COO Wu Xiaobin sells entire 89.8K share position for $27.3M at avg $304.56; stock now at $321.36 (+5.5%)

Wu Xiaobin, President and COO, executed 16 separate sales on August 13–14, 2025, totaling 89,794 shares for $27,347,635.41 at a blended average price of $304.56 per share. This represents a complete liquidation—100.0% of his pre-transaction holdings (89.8K shares) leaving him with zero shares post-transaction. The stock has since appreciated to $321.36, trading at its 52-week high (+0.0% from peak), meaning the insider sold approximately $1.4M in unrealized gains below current market levels. His cross-ticker track record shows a 90-day well-timed sell rate of 40.00%, and his prior three sales at ONC (2025-06-16 and 2025-06-17) all showed positive 30-day returns ranging 4.9–15.7%, but no 90-day outcomes are yet measurable for those recent trades. The timing of this complete exit—occurring as the stock rallies hard (30-day: +15.1%, 90-day: +40.7%) and touches its 52-week high—warrants close scrutiny of BeOne Medicines' forward outlook, particularly given the company's full-year net income was negative despite $1.3B quarterly revenue and +55.0% annual growth.

BeOne Medicines COO Wu Xiaobin sells entire 2.2K share stake ($567.7K) in 3 transactions; exits all holdings at blended $261.27.

Wu Xiaobin, President and COO, executed 3 separate sales totaling 2,173 shares for $567,741.71 over two trading days (June 16–17), reducing his holdings from 2.2K shares to zero—a complete exit of his position. The blended average price of $261.27 compares to the current price of $252.78, meaning he sold above recent market levels. His cross-ticker track record shows 20 prior sells with a 90d well-timed rate of 25.00%, a modest historical timing profile that provides limited insight into whether this particular exit signals foresight. The company reported $1.1B quarterly revenue with +55.0% annual growth but remains unprofitable on a full-year basis, making the strategic rationale for a complete insider liquidation worth monitoring even as recent price momentum (+8.3% over 30 days) suggests near-term upside.

BeiGene COO Wu Xiaobin sells all 51,921 shares for $14.6M at $281.40 blended avg; stock now down 24.9% from 52-week high.

Wu Xiaobin, President, COO & GM China at BeiGene, executed 4 separate sales totaling 51,921 shares for $14,610,370.12, liquidating his entire equity position at a blended average price of $281.40 on April 1, 2025. The complete exit comes as BeiGene stock has retreated 24.9% from its 52-week high of $246.04 and fallen 14.1% over the prior 30 days and 20.9% over 90 days—a significant period of weakness. The timing is notably unfavorable relative to Wu's cross-ticker track record: his prior open-market sells across all tickers showed a 90-day well-timed rate of only 16.67%, indicating he has historically sold before larger declines only in a minority of cases. The company remains unprofitable despite strong 55.0% annual revenue growth, posting a net income of $-121,350,000.00 in the latest quarter on $1,001,599,000.00 in revenue, which adds fundamental uncertainty to the equity valuation at the time of exit.

Wu Xiaobin (President, COO & GM China) sells entire 51,921-share BGNE holding for $13.6M; stock down 24.9% from 52-week high.

Wu Xiaobin executed 4 separate sales totaling 51,921 shares for $13,581,904.65 on 2025-03-05, reducing his holdings from 51,921 shares to 0 shares—a complete exit of his position. The sales were executed at a blended average price of $261.59, but the stock now trades at $184.71, down 24.9% from its 52-week high of $246.04 and down 14.1% over the past 30 days. This full liquidation by a senior operational executive (President, COO & GM China) during a period of significant stock weakness is material, particularly given that BeiGene remains unprofitable on an annual basis (net income of $-121,350,000.00 on revenue of $1,001,599,000.00) despite strong annual growth of 55.0%. The complete exit of the insider's entire stake removes an important indicator of management confidence in the company at current valuations.

BeiGene President/COO Wu Xiaobin sells 51,921 shares for $12.5M, exiting entire holdings at $240.46 avg in 2 days

Wu Xiaobin executed four separate sales totaling 51,921 shares for $12,485,044.71 on 2025-02-18 and 2025-02-20, liquidating 100.0% of his holdings at a blended average price of $240.46. The stock has since declined 24.9% from its 52-week high and trades at $184.71, representing a -14.1% move over the past 30 days and -20.9% over 90 days. While Wu's cross-ticker track record shows a 41.18% well-timed rate across 17 prior sells with an average 90-day return of +5.5%, his prior five sales at BeiGene show mixed timing results, with only 2 of 5 achieving negative 90-day returns (the well-timed outcome for a seller). Against this backdrop, BeiGene itself remains operationally challenged: the company generated $1,001,599,000.00 in quarterly revenue and posted net income of -$121,350,000.00, and despite 73.6% annual revenue growth, it was unprofitable over its most recent full fiscal year. The complete liquidation by a senior operating executive warrants investor attention given the company's unprofitable status and the magnitude of the exit.

BeiGene President Wu Xiaobin sells entire 5,000-share BGNE stake for $1.0M at $200.12 avg in 2 separate sales (Sept 17–19)

Wu Xiaobin, President, COO & GM China, liquidated his entire BGNE holdings through 2 separate sales totaling 5,000 shares for $1,000,614.70, reducing his position from 5.0K shares to zero. The sales occurred at $200.00 and $200.14 on consecutive trading days (2024-09-17 and 2024-09-19), near the 52-week high of $211.15 (current price $198.59, down 6.0% from peak). His cross-ticker track record shows a 50.00% well-timed rate on 15 prior sells with an average 90-day return of +7.6%, indicating historically mixed timing; however, his 5 prior BGNE sales from 2024-09-03 remain unmeasurable at the 90-day horizon. The company is unprofitable (net income $-120.4M in the latest quarter) but growing revenue rapidly (+73.6% annual growth), creating tension between growth metrics and near-term financial performance.

BeiGene President/COO Wu Xiaobin liquidates entire 5,556-share stake for $1,053,676.76 across 5 sales at blended $189.65.

Wu Xiaobin executed a complete exit of his BeiGene position on 2024-09-03, selling all 5,556 shares across 5 separate transactions ranging from $188.16 to $192.04 per share, totaling $1,053,676.76. This represents a 100% reduction from pre-transaction holdings and is notable given his executive rank (President, COO & GM China). His cross-ticker track record shows strong historical timing on sales, with a 100.00% well-timed rate across 10 prior sells (averaging -8.5% 30-day returns and -11.1% 90-day returns after the sale), though at BeiGene specifically his 5 prior sells from June 2024 posted modest near-term declines (-1.1% to -3.4% over 30 days). The stock is currently $191.58, +11.8% over 30 days and +22.5% over 90 days from prior levels, trading 8.4% below its 52-week high of $209.24. The company remains unprofitable (net income -$120.4M on revenue $929.2M last quarter) despite strong 73.6% annual revenue growth, and Wu's complete position liquidation warrants attention to any underlying concerns or material factors beyond routine rebalancing.

BeiGene President Wu Xiaobin sells entire 3,254-share position in 5 transactions totaling $505.2K; all prior sales at BGNE well-timed.

Wu Xiaobin executed a complete liquidation of his BeiGene holdings, selling 3,254 shares across five separate transactions on June 17–18 at prices ranging from $153.66 to $159.00, for a blended average of $155.26. This represents a 100% exit of his pre-transaction position. His prior sale activity at BeiGene shows a compelling timing pattern: 5 of 5 prior sells at this ticker resulted in negative 90-day returns (ranging from -8.2% to -20.3%), meaning the stock fell after each sale—a 100% well-timed rate at the same ticker. The current stock price of $155.54 is -30.9% from the 52-week high and down 7.1% in the last 30 days, placing the stock within the lower half of its trading range. Given that BeiGene is unprofitable (net income $-251.2M in the latest quarter) despite 73.6% annual revenue growth, the insider's consistent pattern of selling ahead of declines at this specific ticker warrants close investor attention.